Andrew Gengos out, John Walker in as Neuraltus CEO

Andrew Gengos.

Andrew Gengos, who led Neuraltus Pharmaceuticals Inc. into a Phase II trial of its experimental treatment for Lou Gehrig's disease, has left the company. Veteran Bay Area biotech executive John Walker, Neuraltus' chairman, took over Aug. 15 as interim CEO, according to a company telephone message.